

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Johannes Bijlsma
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
David Pisetsky

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 12.384

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2017 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Nova Techset Private Limited, Bengaluru & Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 315** What is rheumatoid arthritis? Considering consequences of changed classification criteria
A H M van der Helm-van Mil, A Zink

Recommendations

- 318** EULAR revised recommendations for the management of fibromyalgia
G J Macfarlane, C Kronisch, L E Dean, F Atzeni, W Häuser, E Fluß, E Choy, E Kosek, K Amris, J Branco, F Dincer, P Leino-Arjas, K Longley, G M McCarthy, S Makri, S Perrot, P Sarzi-Puttini, A Taylor, G T Jones
- 329** Consensus-based recommendations for the management of juvenile dermatomyositis
F B Enders, B Bader-Meunier, E Baildam, T Constantin, P Dolezalova, B M Feldman, P Lahdenne, B Magnusson, K Nistala, S Ozen, C Pilkington, A Ravelli, R Russo, Y Uziel, M van Brussel, J van der Net, S Vastert, L R Wedderburn, N Wulffraat, L J McCann, A van Royen-Kerkhof

Clinical and epidemiological research

- 341** Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria
L B Nordberg, S Lillegraven, E Lie, A-B Aga, I C Olsen, H B Hammer, T Uhlig, M K Jonsson, D van der Heijde, T K Kvien, E A Haavardsholm, and the ARCTIC working group
- 346** Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
W Park, D H Yoo, P Miranda, M Brzosko, P Wiland, S Gutierrez-Ureña, H Mikeazane, Y-A Lee, S Smiyan, M-J Lim, V Kadinov, C Abud-Mendoza, HoUng Kim, S J Lee, Yunju Bae, SuYeon Kim, J Braun
- 355** Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
D H Yoo, N Prodanovic, J Jaworski, P Miranda, E Ramiterra, A Lanzon, A Baranaukaite, P Wiland, C Abud-Mendoza, B Oparanov, S Smiyan, HoUng Kim, S J Lee, SuYeon Kim, W Park

- 364** Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?
J K Eriksson, L Jacobsson, K Bengtsson, J Askeling

- 371** Disease activity is associated with reduced left ventricular systolic myocardial function in patients with rheumatoid arthritis
H Midtbo, A G Semb, K Matre, T K Kvien, E Gerds

- 377** Lesional CD4⁺ IFN- γ ⁺ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis
T Maehara, H Matuo, M Ohta, V S Mahajan, M Moriyama, M Yamauchi, J Drijvers, S Nakamura, J H Stone, S S Pillai

- 386** Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
L K Mercer, J Askeling, P Raaschou, W G Dixon, L Dreyer, M L Heiland, A Strangfeld, A Zink, X Mariette, A Finckh, H Canhao, F Iannone, J Zavada, J Morel, J-E Gottenberg, K L Hyrich, J Listing

- 392** Can we use structural lesions seen on MRI of the sacroiliac joints reliably for the classification of patients according to the ASAS axial spondyloarthritis criteria? Data from the DESIR cohort
P A C Bakker, R van den Berg, G Lenczner, F Thévenin, M Reijnen, P Claudepierre, D Wendling, M Dougados, D van der Heijde

- 399** Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs
C P Figueiredo, H Bang, J F Cobra, M Englbrecht, A J Hueber, J Haschka, B Manger, A Kleyer, M Reiser, S Finzel, H-P Tony, S Kleinert, J Wendler, F Schuch, M Ronneberger, M Feuchtenberger, M Fleck, K Manger, W Öchs, M Schmitt-Haendle, H-M Lorenz, H Nuesslein, R Alten, J Henes, K Krueger, J Rech, G Schett

- 408** Improved survival in rheumatoid arthritis: a general population-based cohort study
Y Zhang, N Lu, C Peloquin, M Dubreuil, T Neogi, J A Avina-Zubieta, S K Rai, H K Choi

- 414** Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
G R Burmester, R Landewé, M C Genovese, A W Friedman, N D Pfeifer, N A Varothai, A P Lacerda

- 418** Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression
D Aletaha, F Alasti, JS Smolen

- 422** Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
M Humbert, J G Coghlan, H-A Ghofrani, F Grimminger, J-G He, G Riemekasten, C D Vizza, A Boeckenhoff, C Meier, J de Oliveira Pena, C P Denton

Basic and translational research

- 427** Inhibition of BATF/JUN transcriptional activity protects against osteoarthritic cartilage destruction
J Rhee, S-H Park, S-K Kim, J-H Kim, C-W Ha, C-H Chun, J-S Chun

MORE CONTENTS ►

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

COPE

Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



equator network



When you have finished with this please recycle it

MCOs

The online version of this article contains multiple choice questions hosted on BMJ Learning.

- 435** TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis



OPEN ACCESS

M Rossetti, R Spreafico, A Consolaro, J Y Leong, C Chua, M Massa, S Saidin, S Magni-Manzoni, T Arkechaisri, C A Wallace, M Gattorno, A Martini, D J Lovell, S Albani

- 442** Forced exercise-induced osteoarthritis is attenuated in mice lacking the small leucine-rich proteoglycan decorin

T Gronau, K Krüger, C Prein, A Aszodi, I Gronau, R V Iozzo, F C Mooren, H Clausen-Schaumann, J Bertrand, T Pap, P Bruckner, R Dreier

- 450** Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome

R C Grenn, S Yalavarthi, A A Gandhi, N M Kazzaz, C Núñez-Álvarez, D Hernández-Ramírez, A R Cabral, W J McCune, P L Bockenstedt, J S Knight

- 458** Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis

J S Dekkers, J W Schoones, T W Huizinga, R E Toes, A H van der Helm-van Mil

- 468** Familial chilblain lupus due to a gain-of-function mutation in STING

N König, C Fiehn, C Wolf, M Schuster, E C Costa, V Tüngler, H A Alvarez, O Chara, K Engel, R Goldbach-Mansky, C Günther, M A Lee-Kirsch

Electronic pages

Correspondence

- e3** Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?

G Nocturne, R Seror, X Mariette

- e4** Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne *et al*

L K Mercer, J B Galloway, M Lunt, R Davies, A AL Low, W G Dixon, K D Watson, D PM Symmons, K L Hyrich